A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Moves [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
Arcutis Biotherapeutics (ARQT) has drawn attention after a recent share price move, with the stock closing at US$22.86 and showing mixed performance over the past week, month, and past 3 months. See our latest analysis for Arcutis Biotherapeutics. While the latest 1-day share price return of 3.75% decline and 7-day share price return of 5.50% decline point to fading short-term momentum, the 1-year total shareholder return of 55.30% suggests longer term holders have still seen meaningful gains. If you are comparing Arcutis with other fast growing healthcare names, this could be a good moment to widen the search and check out 34 healthcare AI stocks With Arcutis trading at US$22.86 and an indicated intrinsic discount of 71%, along with a sizeable gap to the consensus price target, you have to ask: is this a genuine opportunity, or is the market already factoring in future growth? Most Popular Narrative: 42.8% Undervalued With Arcutis Biotherapeutics last closing at $22.86 a
Show less
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months [Yahoo! Finance]Yahoo! Finance
- Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 MonthsGlobeNewswire
- Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis GuidelinesGlobeNewswire
- Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in Infants [Yahoo! Finance]Yahoo! Finance
- Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026GlobeNewswire
ARQT
Earnings
- 2/25/26 - Beat
ARQT
Sec Filings
- 4/21/26 - Form S-8
- 4/21/26 - Form ARS
- 4/21/26 - Form DEFA14A
- ARQT's page on the SEC website